Skip to main content

Table 1 Clinico-pathological characteristics of WT Bf-CM patients

From: A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma

Groups Total (N = 211) Training Group (N = 106) Test Group (N = 105)
Gender
 Male 135(64.0%) 73(68.9%) 62(59.0%)
 Female 76(36.0%) 33(31.1%) 43(41.0%
Age At Diagnosis
 Median 62 63.5 61
 Range 25 ~ 87 30 ~ 87 25 ~ 83
 ≤ 58 90(42.7%) 42(39.6%) 48(45.7%)
 > 58 121(57.3%) 64(60.3%) 57(54.3%)
Tumor Tissue Site
 Primary Tumor 38(18.0%) 20(18.9%) 18(17.10%)
 Regional Cutaneous Or Subcutaneous Tissue 38(18.0%) 21(19.8%) 17(16.20%)
 Regional Lymph Node Metastasis 93(44.1%) 46(43.4%) 47(44.80%)
 Distant Metastasis 40(19.0%) 18(17.0%) 22(21.00%)
 Unknown 2(0.9%) 1(0.9%) 1(1.00%)
Pathological Stage
 0 4(1.9%) 1(0.9%) 3(2.90%)
 I 35(16.6%) 13(12.3%) 22(21.00%)
 II 63(29.9%) 33(31.1%) 30(28.60%)
 III 83(39.3%) 43(40.6%) 40(38.10%)
 IV 8(3.8%) 4(3.8%) 4(3.80%)
 Unknown 18(8.5%) 12(11.3%) 6(5.70%)
Anatomic Site
 Head And Neck 16(7.6%) 8(7.5%) 8(7.60%)
 Extremities 108(51.2%) 55(51.9%) 53(50.50%)
 Trunk 56(26.5%) 28(26.4%) 28(26.70%)
 Others/Unknown 31(14.7%) 15(14.2%) 16(15.20%)
Breslow Thickness (mm)
  < 2 54(25.5%) 26(24.6%) 28(26.70%)
 2 ~ 5 60(28.5%) 36(33.9%) 24(22.80%)
  > 5 53(25.1%) 25(23.6%) 28(26.70%)
 Unknown 44(20.9%) 19(17.9%) 25(23.80%)
Radiation Therapy
 Yes 37(17.5%) 20(18.9%) 17(16.20%)
 No 155(73.5%) 75(70.8%) 80(76.20%)
 Unknown 19(9.00%) 11(10.40%) 8(7.60%)
Vital Status
 Yes 81(38.4%) 36(34.0%) 45(42.90%)
 No 130(61.6%) 70(66.0%) 60(57.10%)